AtonRa Partners Sells 352 Shares of Shockwave Medical, Inc. (NASDAQ:SWAV)

AtonRa Partners lowered its holdings in shares of Shockwave Medical, Inc. (NASDAQ:SWAV) by 8.0% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 4,022 shares of the company’s stock after selling 352 shares during the period. Shockwave Medical makes up 1.5% of AtonRa Partners’ investment portfolio, making the stock its 11th largest holding. AtonRa Partners’ holdings in Shockwave Medical were worth $766,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also bought and sold shares of SWAV. Lindbrook Capital LLC increased its holdings in shares of Shockwave Medical by 64.8% during the third quarter. Lindbrook Capital LLC now owns 150 shares of the company’s stock valued at $30,000 after acquiring an additional 59 shares in the last quarter. EverSource Wealth Advisors LLC grew its holdings in shares of Shockwave Medical by 297.4% during the third quarter. EverSource Wealth Advisors LLC now owns 155 shares of the company’s stock valued at $31,000 after buying an additional 116 shares during the last quarter. Asset Management One Co. Ltd. purchased a new stake in shares of Shockwave Medical during the fourth quarter valued at approximately $34,000. Operose Advisors LLC bought a new stake in shares of Shockwave Medical during the third quarter valued at approximately $49,000. Finally, Venturi Wealth Management LLC purchased a new position in Shockwave Medical in the 3rd quarter worth approximately $82,000. Hedge funds and other institutional investors own 95.35% of the company’s stock.

Insider Buying and Selling at Shockwave Medical

In other news, VP Trinh Phung sold 1,287 shares of the firm’s stock in a transaction dated Tuesday, February 6th. The stock was sold at an average price of $232.18, for a total value of $298,815.66. Following the transaction, the vice president now owns 32,933 shares of the company’s stock, valued at $7,646,383.94. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. In related news, VP Trinh Phung sold 1,287 shares of the stock in a transaction that occurred on Tuesday, February 6th. The shares were sold at an average price of $232.18, for a total value of $298,815.66. Following the completion of the sale, the vice president now directly owns 32,933 shares of the company’s stock, valued at approximately $7,646,383.94. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Dan Puckett sold 3,406 shares of Shockwave Medical stock in a transaction that occurred on Thursday, February 1st. The shares were sold at an average price of $229.76, for a total transaction of $782,562.56. Following the transaction, the chief financial officer now directly owns 27,732 shares in the company, valued at approximately $6,371,704.32. The disclosure for this sale can be found here. Over the last quarter, insiders sold 89,813 shares of company stock valued at $22,863,919. Company insiders own 3.40% of the company’s stock.

Shockwave Medical Stock Performance

Shares of SWAV traded down $0.49 on Monday, reaching $329.51. The company’s stock had a trading volume of 436,668 shares, compared to its average volume of 948,381. Shockwave Medical, Inc. has a 12-month low of $157.00 and a 12-month high of $331.58. The stock has a market capitalization of $12.32 billion, a P/E ratio of 85.14, a PEG ratio of 2.45 and a beta of 0.92. The company has a debt-to-equity ratio of 1.09, a current ratio of 11.76 and a quick ratio of 10.73. The stock’s 50 day simple moving average is $294.88 and its two-hundred day simple moving average is $233.64.

Shockwave Medical (NASDAQ:SWAV) last issued its quarterly earnings results on Thursday, February 15th. The company reported $1.16 earnings per share for the quarter, topping the consensus estimate of $0.92 by $0.24. The business had revenue of $202.98 million for the quarter, compared to analysts’ expectations of $199.43 million. Shockwave Medical had a net margin of 20.17% and a return on equity of 23.97%. The company’s revenue was up 41.0% compared to the same quarter last year. During the same quarter last year, the company posted $3.71 EPS. Research analysts forecast that Shockwave Medical, Inc. will post 4.94 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

SWAV has been the topic of several recent analyst reports. Wells Fargo & Company increased their target price on Shockwave Medical from $200.00 to $210.00 and gave the company an “equal weight” rating in a research note on Friday, February 16th. Piper Sandler increased their price objective on Shockwave Medical from $290.00 to $360.00 and gave the company an “overweight” rating in a research report on Tuesday, April 2nd. TheStreet raised Shockwave Medical from a “c+” rating to a “b” rating in a research report on Thursday, February 15th. Morgan Stanley restated an “equal weight” rating and set a $335.00 target price (up previously from $285.00) on shares of Shockwave Medical in a research note on Monday, April 8th. Finally, SVB Leerink reiterated a “market perform” rating and issued a $335.00 price target (down from $361.00) on shares of Shockwave Medical in a research note on Monday, April 8th. Ten equities research analysts have rated the stock with a hold rating and one has assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $309.11.

Shockwave Medical Company Profile

Shockwave Medical, Inc, a medical device company, develops and commercializes intravascular lithotripsy (IVL) technology for the treatment of calcified plaque in patients with peripheral and coronary vascular, and heart valve diseases in the United States and internationally. The company offers products for the treatment of peripheral artery disease (PAD), including M5 IVL catheter and M5+ IVL catheter, which are five-emitter catheters used in IVL system in medium-diameter vessels; S4 IVL catheter, a four-emitter catheter for use in IVL system in small-diameter vessels; and L6 IVL catheter, a six-emitter catheter used for IVL System in large diameter vessels.